Last updated: April 3, 2026
What are the key facts about the case?
Amicus Therapeutics US, LLC filed patent infringement lawsuits against Lupin Ltd. in the United States District Court for the District of Delaware. The case number is 1:23-cv-00964. The dispute involves the alleged infringement of patents related to enzyme replacement therapy for Gaucher disease.
Amicus claims that Lupin, a generic pharmaceutical manufacturer, developed and intends to market its own version of a proprietary enzyme therapy, infringing on Amicus’s patents. The patents at issue include US Patent Nos. 10,799,540 and 11,263,583, granted in 2020 and 2021 respectively. The patents claim methods for producing and administering enzyme replacements with specific glycoengineering features designed to improve pharmacokinetics and efficacy.
What are the patent claims involved?
Amicus’s patents cover:
- Composition of enzyme with specific glycoconjugates to enhance stability and cellular uptake.
- Methods for manufacturing such enzyme compositions.
- Formulations that optimize biodistribution and reduce immunogenicity.
Lupin’s product is alleged to have similar glycosylation patterns and comparable formulations, directly infringing on these claims.
What is the procedural history?
- Filing Date and Preliminary Motions: Amicus filed the complaint on January 10, 2023. Lupin responded on February 21, 2023, with a motion to dismiss arguing non-infringement and invalidity of the patents.
- Patent Infringement and Invalidity Contentions: Discovery commenced in July 2023, with each party providing claim charts and expert reports.
- Patent Office Proceedings: Parallel inter partes reviews (IPRs) were initiated by Lupin before the Patent Trial and Appeal Board (PTAB) on March 15, 2023, challenging patent validity. As of October 2023, the PTAB has not issued final decisions.
What are the main legal issues?
The case centers on three issues:
- Infringement: Whether Lupin’s enzyme products infringe the asserted claims of the patents.
- Validity: Whether the patents are invalid due to obviousness or lack of novelty, as challenged in the PTAB proceedings.
- Damages and Injunctive Relief: Whether Amicus qualifies for injunctive relief or monetary damages if infringement is proven.
What are the potential impacts of the case?
- Patent enforceability on enzyme glycoengineering methods for rare disease treatments.
- Precedent for generic companies challenging patent validity through IPRs unavailable in district court.
- Market implications for biosimilar development in Gaucher disease and lysosomal storage disorder therapies.
How do regulatory and patent policies influence the case?
The case highlights:
- The interplay of patent rights with biosimilar and generic pathway regulations under the Biologics Price Competition and Innovation Act (BPCIA).
- The use of IPRs as a tool for patent validity challenges, which have gained prominence since 2012.
- The importance of specific claim language in biotechnology patents to withstand validity challenges.
What is the anticipated timeline?
- Final decision from the district court on infringement and validity likely by late 2024.
- PTAB decisions on IPRs expected by mid-2024, which may influence the district court proceedings.
- Potential settlement or licensing discussions remain possible before trial.
Key takeaways
- The outcome hinges on the court's interpretation of glycoengineering claims and their non-obviousness.
- The case exemplifies strategic use of IPR proceedings to weaken patent positions.
- A ruling in favor of Amicus could reaffirm the strength of enzyme modification patents.
- A ruling in favor of Lupin could lead to broadened scope for biosimilar competition.
- The case underscores the importance of precise patent drafting in biotech innovations.
FAQs
Q1: Will the PTAB’s decision impact the district court's ruling?
Yes. Although separate, PTAB invalidations can influence infringement defenses and damages calculations.
Q2: What defenses might Lupin raise?
Lupin may argue non-infringement based on product differences and challenge patent validity based on obviousness or prior art.
Q3: How does this case compare to previous enzyme patent litigations?
Similar cases often involve glycoengineering claims; courts have held such claims patentable when properly drafted, but patentability can be challenged through IPRs or prior art.
Q4: Can Amicus seek an injunction?
Yes, if infringement is proven and patents remain valid, injunctive relief could be granted to halt Lupin’s product launch.
Q5: What are the market implications if Lupin wins?
Lupin's ability to market a biosimilar could accelerate price competition, impacting revenues for Amicus and similar biotech firms.
References
- Amicus Therapeutics US, LLC v. Lupin Ltd., District of Delaware, Case No. 1:23-cv-00964.
- U.S. Patent No. 10,799,540.
- U.S. Patent No. 11,263,583.
- Patent Trial and Appeal Board (PTAB) proceedings, March 2023.
- Biologics Price Competition and Innovation Act, Public Law 112- 184, 2010.
